Full View

Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis

C Barro, BC Healy, Y Liu, S Saxena… - Neurology …, 2022 - AAN Enterprises
Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …
被引用次数：58 相关文章
[HTML] neurology.org

[HTML][HTML] Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

C Barro, BC Healy, Y Liu, S Saxena… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …
[HTML] nih.gov

[HTML][HTML] Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

C Barro, BC Healy, Y Liu, S Saxena… - Neurology® …, 2023 - ncbi.nlm.nih.gov
Methods We leveraged our Comprehensive Longitudinal Investigation of MS at the Brigham
and Women's Hospital (CLIMB) natural history study, which includes clinical, MRI data and …

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

C Barro, BC Healy, Y Liu, S Saxena… - Neurology (R) …, 2022 - pubmed.ncbi.nlm.nih.gov
Background and objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.

C Barro, BC Healy, Y Liu, S Saxena, A Paul… - Neurology (r) …, 2022 - europepmc.org
Methods We leveraged our Comprehensive Longitudinal Investigation of MS at the Brigham
and Women's Hospital (CLIMB) natural history study, which includes clinical, MRI data and …